Latest News for: oral presentation

Edit

Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 ...

Polk County Itemiser-Observer 21 Mar 2026
... for two oral presentations at the 2026 American ....
Edit

D3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation ...

Magic Valley 20 Mar 2026
(PRNewsfoto/D3 Bio, Inc.) ... .
Edit

D3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation at Clinical Plenary Session

PR Newswire 20 Mar 2026
Notably, two of the five abstracts have been selected for oral presentations at the Clinical Trials Plenary Session and the Clinical Trials Mini-Symposium, respectively ... Details of the oral presentations are as follows.
Edit

Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting

PR Newswire 20 Mar 2026
Late-Breaking Research Oral Presentation (Abstract 79863) ... ePoster Oral Presentation (Abstract 73858).
Edit

Persica Pharmaceutical’s PP353 Phase 1b Data Selected for Oral Presentation at the American Society of ...

Norfolk Daily News 19 Mar 2026
ASIPP presentation follows publication of positive data from PP353 Phase 1b Modic Trial in The Lancet’s ... .
Edit

Altesa BioSciences' Treatment for Rhinovirus Infections in People with Respiratory Conditions, Vapendavir, Selected for Oral Presentation at the International Society for Antiviral Research Conference (ICAR) 2026

PR Newswire 19 Mar 2026
The oral presentation, entitled "Vapendavir, a Rhinovirus Capsid Inhibitor, Exhibits Activity Against Type C Rhinoviruses" will be presented by Katherine Squires, PhD, Altesa Vice President for Research and Translational Science.
Edit

AD/PD 2026 Oral Presentation: RewinD-LB Clinical Study Results (604a1f) (Cervomed Inc)

Public Technologies 19 Mar 2026
‌Neflamapimod is an oral, small molecule drug that selectively inhibits p38α, a key synaptic dysfunction in the basal forebrain cholinergic system ... ‌Summary of other key results from the Phase 2b RewinD-LB study (full results presented at CTAD 2025).
Edit

Brenig Therapeutics Announces Oral Presentation of Phase 1 Data for BT-267 at AD/PD™ 2026, and ...

The Citizens 18 Mar 2026
(Brenig), a clinical-stage biotechnology company advancing ...
Edit

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting (Alumis Inc)

Public Technologies 18 Mar 2026
). The text version of this document is not available ... Disclaimer. Alumis Inc.
Edit

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 ...

Nasdaq Globe Newswire 18 Mar 2026
IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by ...
Edit

Synthekine Announces AACR 2026 Oral Presentation of Updated Phase 1a/1b Clinical and Translational Data for ...

Business Wire 18 Mar 2026
MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, ...
Edit

Circio selected for oral presentation at prestigious ASGCT annual meeting (Circio Holding ASA)

Public Technologies 18 Mar 2026
) * An abstract submitted by Circio has been selected for an oral presentation ... therapy, today announces that it has been selected for an oral presentation at ... submitted abstracts are accepted for oral presentation.
Edit

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting (Inflarx NV)

Public Technologies 18 Mar 2026
"It is an honor that our Phase 3 study data for vilobelimab in pyoderma gangrenosum (PG) have been selected for a late-breaking oral presentation at AAD ... Oral presentation.
Edit

Aspen Neuroscience Announces Positive 12‑Month Data from its ASPIRO Clinical Trial in a Late‑Breaking Oral Presentation at the AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases

PR Newswire 18 Mar 2026
... clinical trial in a late‑breaking oral presentation at the AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases, taking place March 17–21, 2026 in Copenhagen, Denmark.
Edit

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation

Caledonian Record 17 Mar 2026
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting ....

Article Search

tools
×
×
×
×